title: All-trans-retinoic acid limits restenosis after balloon angioplasty in the focally atherosclerotic rabbit : a favorable effect on vessel remodeling.
abstract: All-trans-retinoic acid (atRA) has potent in vitro effects on a number of processes involved in vascular injury and repair, such as modulating smooth muscle cell (SMC) proliferation and inducing SMC differentiation, and may play an important role in the in vivo response to vascular injury. We hypothesized that atRA would limit restenosis after balloon angioplasty through SMC-modulated changes in plaque size and vessel geometry. Balloon angioplasty was performed on rabbits with focal femoral atherosclerosis randomized to treatment with atRA or saline. At 28 days after balloon angioplasty, minimal luminal diameter was significantly larger in the atRA group (1.24+/-0.17 versus 1.12+/-0.22 mm, P=0.02). Histomorphometry confirmed a larger lumen area (0.51+/-0.20 versus 0. 34+/-0.13 mm(2), P=0.004) in the atRA group, with no difference in absolute plaque area. Internal elastic lamina and external elastic lamina areas were significantly larger in the atRA group (0.89+/-0. 27 versus 0.66+/-0.24 mm(2), P=0.001, and 1.29+/-0.38 versus 0. 98+/-0.32 mm(2), P=0.001, respectively). Vessel sections exhibited significantly more alpha-actin and desmin immunostaining (P=0.01) in the atRA-treated group. No differences in early cellular proliferation and collagen content were detected with the use of bromodeoxyuridine. In this atherosclerotic model of vascular injury, atRA limits restenosis after balloon angioplasty by effects secondary to overall vessel segment enlargement at the angioplasty site rather than by effects on plaque size or cellular proliferation. Increased alpha-actin and desmin immunostaining suggest a possible role for phenotypic modulation of SMCs in this favorable remodeling effect.
authors.affiliation: Cardiovascular Division, Department of Medicine, University of VirginiaHealth Sciences Center, Charlottesville, VA 22908, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Wiegman
authors.forename: W L
authors.initials: WL
authors.lastname: Barry
authors.forename: J A
authors.initials: JA
authors.lastname: McPherson
authors.forename: C A
authors.initials: CA
authors.lastname: McNamara
authors.forename: L W
authors.initials: LW
authors.lastname: Gimple
authors.forename: J M
authors.initials: JM
authors.lastname: Sanders
authors.forename: G G
authors.initials: GG
authors.lastname: Bishop
authors.forename: E R
authors.initials: ER
authors.lastname: Powers
authors.forename: M
authors.initials: M
authors.lastname: Ragosta
authors.forename: G K
authors.initials: GK
authors.lastname: Owens
authors.forename: I J
authors.initials: IJ
authors.lastname: Sarembock
mesh_terms: D000199:Actins / Q000378:metabolism; D000800:Angioplasty, Balloon / Q000009:adverse effects*; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy*; D002455:Cell Division / Q000187:drug effects; D003094:Collagen / Q000378:metabolism; D003893:Desmin / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011817:Rabbits; D012008:Recurrence; D013997:Time Factors; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D000199:Actins; D003893:Desmin; D014212:Tretinoin; D003094:Collagen